Budget 2026 gives biologics & biosimilars a major policy boost

India is set to become a global biopharmaceutical manufacturing hub. Finance Minister Nirmala Sitharaman announced a dedicated ₹10,000 crore program over five years. This initiative focuses on biosimilars and biologics, crucial for treating non-communicable diseases. The move aims to boost manufacturing, regulation, and clinical trials, positioning India for future global competition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/O5kjGqs
via IFTTT